CTLA4 and neoplasm: To test whether tumor-specific splicing-derived neoepitopes may be associated to the patient response to immune therapy, we applied ISOTOPE to RNA-seq data from two cohorts of melanoma patient samples prior to treatment with anti-CTLA4 [4] or anti-PD1 [30] (S6 and S7 Tables).